22 withdrawn. 22 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Withdrawn 22 |
| Phase 3 | 4 | Withdrawn 4 |
| Phase 1 | 3 | Withdrawn 3 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure. Human albumin, Saline solution - Septic Shock | Phase 2 | Withdrawn | Albimmune SL | 2024-02-01 | 2024-07-31 | |
| CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 DeltaRex-G - COVID-19, Cytokine Storm | Phase 1 / Phase 2 | Withdrawn | Aveni Foundation | 2022-12-12 | 2025-02-24 | |
| Gram Type Infection-Specific Sepsis Identification Using Machine Learning InSight - Sepsis, Severe Sepsis | Phase 2 | Withdrawn | Dascena | 2022-05-01 | 2021-09-23 | |
| Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection Tazemetostat - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 2 | Withdrawn | Loma Linda University | 2022-01-01 | 2021-11-22 | |
| Anakinra, COVID-19, Cytokine Storm Anakinra, 0.9% Saline - Covid19, Cytokine Storm | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2021-12-01 | 2022-01-25 | |
| Safety and Efficacy of Ruxolitinib for COVID-19 Ruxolitinib - COVID-19 | Phase 2 / Phase 3 | Withdrawn | University of Colorado, Denver | 2021-07-01 | 2021-03-08 | |
| Safety and Efficacy of Baricitinib for COVID-19 Baricitinib - COVID-19 | Phase 2 / Phase 3 | Withdrawn | University of Colorado, Denver | 2021-03-01 | 2021-03-08 | |
| Red Cell Rejuvenation for the Attenuation of Transfusion Associated Organ Injury in Cardiac Surgery rejuvesol Solution, Standard Care - Organ Failure, Multiple, Inflammation | Phase 2 | Withdrawn | University of Leicester | 2020-12-01 | 2021-04-29 | |
| Subpopulation-Specific Sepsis Identification Using Machine Learning CustomSight - Sepsis, Severe Sepsis | Phase 2 | Withdrawn | Dascena | 2020-12-01 | 2021-09-23 | |
| RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM Doxycycline, Placebo - Cytokine Storm, SARS-CoV-2 | Phase 2 | Withdrawn | Temple University | 2020-06-22 | 2021-04-19 | |
| RCT of Sepsis Machine Learning Algorithm InSight - Sepsis, Severe Sepsis | Phase 2 | Withdrawn | Dascena | 2020-01-01 | 2021-09-23 | |
| Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery Vasopressin, Norepinephrine - Circulatory Shock, Non-cardiac Surgery | Phase 2 / Phase 3 | Withdrawn | University of Sao Paulo | 2019-01-01 | 2023-10-05 | |
| Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis Liquid Nutrition, Insulin Drip - Septic Shock | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-10-01 | 2017-02-24 | |
| Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Single bolus of Placebo of CicloMulsion® (Neurovive)., Single bolus of cyclosporine A (CicloMulsion®, Neurovive) - Acute Myocardial Infarction | Phase 2 | Withdrawn | Hospices Civils de Lyon | 2015-09-01 | 2016-03-16 | |
| Pre-Hospital Use of Plasma for Traumatic Hemorrhage Plasma, Normal saline - Shock, Hemorrhagic | Phase 2 / Phase 3 | Withdrawn | Virginia Commonwealth University | 2014-11-01 | 2016-02-23 | |
| Phase 2c Dose Comparison Study of MP4OX in Trauma MP4OX, Control - Trauma, Hemorrhagic Shock | Phase 2 | Withdrawn | Sangart | 2013-12-01 | 2013-10-31 | |
| Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) tocilizumab - Hemophagocytic Lymphohistiocytosis | Phase 2 | Withdrawn | Children's Hospital of Philadelphia | 2013-12-01 | 2022-03-28 | |
| Pharmacology of Exenatide in Pediatric Sepsis Exenatide, Exenatide vehicle - Septic Shock, Inflammation | Phase 1 / Phase 2 | Withdrawn | Seattle Children's Hospital | 2012-10-01 | 2017-10-05 |
Showing 20 of 22. Sign in to see all of them.
Cytokine Release Syndrome (9) · Sepsis (8) · Shock, Septic (8) · COVID-19 (4) · Inflammation (4) · Disease (3) · Hemorrhage (2) · Shock, Hemorrhagic (2) · Wounds and Injuries (2) · Acidosis, Lactic (1) · Burkitt Lymphoma (1) · Diabetes Insipidus (1) · Lymphohistiocytosis, Hemophagocytic (1) · Multiple Myeloma (1)
Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Systemic Inflammatory Response Syndrome (18) · Infections (14) · Inflammation (14) · Virus Diseases (5) · Coronaviridae Infections (4) · Coronavirus Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4)
Saline Solution (4) · Interleukin 1 Receptor Antagonist Protein (2) · Doxycycline (1) · Enteral Nutrition (1) · Exenatide (1) · Heparin (1) · Norepinephrine (1) · PEG-hemoglobin (1) · Serum Albumin, Human (1) · Standard of Care (1) · Vasopressins (1) · baricitinib (1) · maleimide-polyethylene glycol-modified hemoglobin, MP4 (1) · polynitroxylated pegylated hemoglobin (1) · retrovector encoding mutant anti-cyclin G1 (1)
Dascena (3) · University of Colorado, Denver (3) · Albimmune SL (1) · Aveni Foundation (1) · Children's Hospital of Philadelphia (1) · Gil Joon Suh (1) · Hospices Civils de Lyon (1) · Jack Khouri, MD (1) · Kevin McNerney (1) · Loma Linda University (1) · M.D. Anderson Cancer Center (1) · Sangart (1) · Seattle Children's Hospital (1) · Temple University (1) · University of Leicester (1)
United States (9) · France (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Germany (1) · Israel (1) · New Zealand (1) · Norway (1) · South Africa (1) · South Korea (1) · Switzerland (1)
Ritankar Das, MSc (3) · Joaquin Espinosa, PhD (2) · Arthur M Feldman, MD, PhD (1) · Bruce D Spiess, MD, FAHA (1) · Ciprian P Gheorghe, MD, PhD (1) · David Teachey, MD (1) · Diego de Villalobos, MD (1) · Eric Bonnefoy-Cudraz, MD, PhD (1) · Frank V. Booth, BCh, FACS (1) · Gavin J Murphy, Prof (1) · Gil Joon Suh, professor (1) · Iris Y Navarro-Millan, MD, MSPH (1) · Jack Khouri, MD (1) · Juliano P Almeida, MD, PhD (1) · Karim Brohi, MD (1)
PMID 16616623, PMID 19534818, PMID 26220293, PMID 27841822, PMID 28183347, PMID 9403749
K12TR005104 (1)